SAN JOSE, Calif. / Apr 25, 2023 / Business Wire / Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming investor conferences. Outset will participate in the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023, and the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023.
Event: Bank of America Securities 2023 Health Care Conference
Date: Tuesday, May 9, 2023
Time: 1:40pm PT / 4:40pm ET
Event: RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 17, 2023
Time: 5:00am PT / 8:00am ET
Live and archived webcasts of the fireside chats will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Last Trade: | US$0.70 |
Daily Change: | -0.09 -11.82 |
Daily Volume: | 795,574 |
Market Cap: | US$36.370M |
November 15, 2024 October 23, 2024 August 07, 2024 June 03, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB